Drugs / AD5F35-LMP-1/LMP-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00589186 | Nov 2007 → Dec 2009 | head and neck cancer | National Cancer Centre, Singapore | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD5F35-LMP-1/LMP-2 | “Patients receive vaccination with autologous DCs transduced with AD5F35-LMP-1/LMP-2 intradermally every 2 weeks for a total of 5 vaccinations.” NCT00589186 ↗ |
| Modality | Cell therapy | “autologous dendritic cells” NCT00589186 ↗ |